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Objective/background: Acute myeloid leukemia (AML) is defined as leukemic blast reproduc-
tion in bone marrow. Chromosomal abnormalities form different subgroups with joint clinical
specifications and results. t(8;21)(q22;q22) and inv(16)(p13;q22) form core binding factor-
AML (CBF-AML). c-kit mutation activation occurs in 12.8–46.1% of adults with CBF leukemia.
These mutations occur in 20–25% of t(8;21) and 30% of inv(16) cases.
Methods: In this systematic review, we searched different databases, including PubMed, Sco-
pus, and Embase. Selected articles were measured based on the inclusion criteria of this study
and initially compared in terms of titles or abstracts. Finally, articles relevant to the subject of
this review were retrieved in full text. Twenty-two articles matched the inclusion criteria and
were selected for this review.
Results: In this study, c-kitmutations were associated with poor prognosis in AML patients with
t(8;21) and inv(16). In addition, these mutations had better prognostic effects on AML patients
with inv(16) compared with those with t(8;21).loid Leu-
2 H. Ayatollahi et al.
Please cite this article in press as: Aya
kemia: A Systematic Review ..., HematConclusion: According to the results of this study, c-kit mutations have intense, harmful
effects on the relapse and white blood cell increase in CBF-AML adults. However, these muta-
tions have no significant prognostic effects on patients.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Acute myeloid leukemia (AML) is defined as an increase of
myeloid blasts in bone marrow [1]. The mean age of AML
patients is 67 years; this means that AML occurs in old age
[2]. Nonetheless, cytogenetic and molecular genetic abnor-
malities play a pivotal role in AML pathogenesis—the most
prevalent AML chromosomal abnormalities are t(8;21)(q22;
q22), inv(16)(p13;q22), and t(6;9)(p23;q34), which are
described as core binding factor-AML (CBF-AML) [1,3,4].
According to previous studies, this group constitutes 5–8%
of all AML cases [2–4]. In fact, AML with fused transcripts
such as RUNX1-RUNX1T1 t(8;21) and CBFB-MYH11 inv(16)
are recognized as CBF-AML; they are determined by their
molecular level through gene infraction which encodes var-
ious CBF subunits [3]. t(8;21)(q22;q22) arises in approxi-
mately 8% of de novo AML patients and is associated
morphologically with AML-M2 subtype [4].
Patients with CBF-AML consist of about 15% of all AML
cases, which is usually more frequent in older patients.
The median age of these patients is considerable lower
and the prognosis is better compared with normal karyotype
AMLs or other chromosome aberrations. This favorable con-
sequence is associated with a higher complete remission
(CR) rate and lower relapse incidence [5–7].
t(8;21) or inv(16) chromosomal rearrangements lead to
novel chimeric fusion formation which contain a CBF com-
plex gene. CBF complex is composed of CBF-a (AML1) and
CBF-b gene infractions which encode CBF subunits. They
are regulators of hematopoiesis that affects CBF-AML
[8–10]. According to recent studies, this translocation is
associated with a high white blood cell (WBC) count and it
has been considered as a significant predictor in a study
by Nguyen et al. [11,3,4]. Moreover, inv(16) and t(16;16)
(p13;q22) are known to have a significant correlation with
AML-M4Eo [3].
In general, CBF-AML has a high CR rate and extended CR
time, particularly in the presence of high-dose cytarabine.
It leads to a better prognosis of CBF-AML compared with
cases with normal karyotypes or other chromosomal aberra-
tions [4,11]. Mutations in Class III receptor tyrosine kinase
coding genes, such as c-kit, cause other molecular disorders
which lead to myeloid leukemia. c-kit expression occurs in
myeloblasts and is present in 60–80% of AML patients
[12]. Additionally, c-kit activation mutations happen in
12.8–46.1% of CBF leukemia adult patients [4,12]. These
mutations mostly occur in exon 8 or 17 and are observed
in 20–25% of t(8;21) and 30% of inv(16) cases [4,12].
To date CBF-AML has a high remission rate and survival
possibilities. Nonetheless, because half of CBF-AML patients
have not been treated yet, it is necessary to evaluate other
markers to recognize patients who do not respond to usualtollahi H et al., Prognostic Importa
ol Oncol Stem Cell Ther (2016), htttherapy; better cognition of CBF-AML pathophysiology such
as c-kit mutation which affects disease prognosis will help
to develop new therapeutic methods [13–16]. Some studies
have proposed that the presence of c-kit mutations or per-
manence of minimal residual disease may be correlated
with a higher incidence of relapse and worse outcome
[8–10].
Contradictory results have been reported about the prog-
nostic significance of kit mutation. Several studies have
shown that kit mutation is correlated with a decreased
remission duration and overall survival (OS) of CBF-AML
patients [4,13,15,16], while some studies expressed that
kit mutations do not affect CBF-AML prognostic results
[17,18]. c-kit mutation may be helpful to predict disease
consequence of CBF-AML cases and it can be applicable as
a novel remedial target for patients who underwent
chemotherapy and did not have any therapeutic interven-
tions. About 90% of CBF-AML patients achieve CR after
anthracycline- and cytarabine-based induction chemother-
apy [18–20].
A high dose of cytarabine which is used for postremission
treatment (HiDAC; 3 g/m2 twice a day on Day 1, Day 3, and
Day 5) results in a better survival rate compared with inter-
mediate and lower doses (400 mg/m2 and 100 mg/m2,
respectively, as a continuous infusion on the 1st to 5th
days). This finding is reported by Cancer and Leukemia
Group B (CALGB) [5].
A study in 2011 by HOVON/SAKK group (Dutch Belgian
Cooperative Trial Group for Hemato-oncology/Swiss Group
for Clinical Cancer Research) achieved the same conclusions
for CBF-AML patients who had been treated with multiagent
chemotherapy with cytarabine at a cumulative dose of
13.4 g/m2 (IDAC) and 26 g/m2 (HiDAC). This study also
showed similar event-free survival and OS for patients who
treated with IDAC and HiDAC (event-free survival at 5 years:
58% vs. 47%; OS at 5 years: 64% vs. 67%) [19,21]. A case study
showed that patients with t(8;21) and c-kit mutant gene
have major molecular response to tyrosine-kinase inhibitor
drugs always. They concluded that tyrosine-kinase inhibitor
is useful to reduce kit positive AML symptoms [22,23]. A
Japanese study in 2013 provided further evidence for HiDAC
benefits in postremission treatment of CBF-AML compared
with low-dose of cytarabine [5].
According to several studies, there is a significant corre-
lation between age increment and c-kit activating muta-
tions, which lead to a high relapse and low survival rate in
CBF-AML groups [4]. Nevertheless, different OS rates have
been reported for CBF-AML patients with c-kit mutations
compared with others [3]. To our knowledge, prognosis of
c-kit mutations in AML patients has not been assessed sys-
tematically. This systematic review aimed to evaluate the
prognostic significance of c-kit mutations in CBF-AML
patients within the age range of 15 to 90 years.nce of C-KIT Mutations in Core Binding Factor Acute Myeloid Leu-
p://dx.doi.org/10.1016/j.hemonc.2016.08.005
In addition, relevant studies in the 
irst search n=6784 
Studies evaluated in detail n=60
Studies excluded by 
primary screening of 
titles and abstracts 
(n =6724)
Studies consisted in the review 
systematic n=22
Studies excluded 
due to utilizing 
as topical n=38
Fig. 1 Preferred Reporting Items for Systematic Reviews and
Meta-analyses Flow Diagram: Screening Procedure of Selected
Articles.
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Search strategy and article selection
In this systematic review, we conducted a literature search
in different databases, including PubMed, Scopus, and
Embase databases. Cochrane extracted data until July
2015 and some key words were applied. The keywords used
are as follows: c-kit and ‘‘core binding factor acute myeloid
leukemia”, survival, c-kit and ‘‘acute myeloid leukemia,
prognosis”, c-kit and ‘‘core binding factor acute myeloid
leukemia”, ‘‘stem cell factor receptor”, ‘‘core binding fac-
tor acute myeloid leukemia” and survival, and ‘‘acute mye-
loid leukemia” and survival were in the cross-reference
search of cohort articles. References lists of all primary
studies were reviewed as well as review articles, in order
to identify the studies which cannot be found via a comput-
erized search.
To determine the competency of articles, titles and
abstracts were investigated thoroughly by one of the
researchers (Ayatollahi H). Eventually, only 22 articles were
compatible with our inclusion criteria, and were reviewed in
present study (Table 1). The search methodology is depicted
in the preferred reporting items for systematic reviews and
meta-analyses flow diagram (Fig. 1).
After measuring valid articles based on the inclusion cri-
teria, the titles and abstracts were compared, and articles
relevant to the subject of this study were retrieved in full
text.
The inclusion criteria of this study were as follows: (1)
published controlled clinical trials until July 2015; (2) pub-
lished articles in English; (3) articles with survival data
based on c-kit status (e.g., c-kit mutations and wild-type
c-kit); and (4) articles with survival data in response to ther-
apy (e.g., CR, disease-free survival, OS, and prognosis). The
exclusion criteria of this study were as follows: (1) studies
with sample sizes smaller than 10 patients; (2) published
lectures, commentaries, review articles, case reports, and
articles in any languages except English; (3) performed stud-
ies on extracted samples from cell lines and tissue cultures;
(4) animal experiments and in vitro studies; (5) studies con-
ducted on patients under 15 years of age; and (6) flow
cytometry analyses.
Collected data for the present review included informa-
tion about authors, publication year, place of study, patient
characteristics (e.g., age range, median WBC count), c-kit
mutations, OS rate, prognosis, number of participants in
experimental groups, control groups, and inv(16) and t
(8;21) subgroups.Results
A detailed review of coherent data which were extracted
from relevant papers is presented in Table 1. All selected
articles were retrospective evaluations of the prognostic
significance of the c-kit molecular marker. Studied popula-
tions of selected research were from different nationalities
and clinical research groups. Besides, data in all the
selected papers were obtained from evaluation of prognos-
tic results of genetic tests prospectively. Also, all studiesPlease cite this article in press as: Ayatollahi H et al., Prognostic Importa
kemia: A Systematic Review ..., Hematol Oncol Stem Cell Ther (2016), httwere conducted on CBF-AML patients with inv(16) and t
(8;21) genetic abnormalities, and the number of studied
cases were between 23 and 425.
Selected articles were classified into the following
groups based on sample sizes: 20–100 patients (12 articles)
[3,4,24–33], 100–200 patients (6 articles) [8,14,34–37],
200–300 patients (1 article) [7], 300–400 patients (2 arti-
cles) [16,38], and 400–500 patients (1 article) [16]. In total,
c-kit mutations were detected in 10.9–46.2% of the studied
patients (mean: 31%).
In this review, c-kit mutations were compared between
two AML groups, including cases with t(8;21) and those with
inv(16). These two categorizations were present in all the
reviewed articles except for those listed in Table 2. The
majority of the studies applied a direct sequencing method
and different forms of polymerase chain reaction (PCR),
including reverse-transcription PCR, methyl-binding PCR,
and real-time PCR to detect c-kit mutations. In addition,
four studies used high-performance liquid chromatography
(HPLC) for c-kit mutations detection (Table 2)
[16,24,34,35].
All the reviewed studies were retrospective with regards
to the prognostic significance of c-kit mutations. Addition-
ally, 11 studies reported c-kit mutation frequencies in inv
(16) and t(8;21) patients separately. Mean WBC count
separation was observed between patients with inv(16)
and t(8;21) in only nine articles, all of which (expect one)
[36] indicated that WBC counts had significant
increments in inv(16) patients compared with t(8;21) cases
[4,24,31,33,35,38,39]. Seven out of these articles
expressed that c-kit mutations had significant
increment in inv(16) patients compared with t(8;21)
patients [4,8,14,24,33,35,38], while three articles statednce of C-KIT Mutations in Core Binding Factor Acute Myeloid Leu-
p://dx.doi.org/10.1016/j.hemonc.2016.08.005
Table 1 Data extraction from included studies investigating the effect of C-KIT in core binding factor-acute myeloid leukemia. NR: data not reported. Note: NR=data not
reported; Ref.=reference.
Ref. First author Publication (region, year) Participants, n c-kit mutations (%) inv(16) subgroup t(8;21) subgroup c-kit mutation
inv(16) subgroup t(8;21) subgroup
[9] Peter Paschka Oldenburg, Germany, 2012 176 37 176 NR 37% NR
[24] Lars Bullinger Palo Alto, CA, 2007 93 22 51 38 24% 16%
[25] Yuan Wang Beijing, China, 2014 92 64 NR 51 NR 64%
[26] Roberto Cairoli Bologna, Italy, 2013 58 25.9 58 NR 25.9 NR
[16] Christopher Allen London, UK, 2013 354 42 155 199 20 22%
[40] Jung-Hoon Yoon Seoul Korea, 2014 264 34.8 71 193 NR
[39] Di Wang Hubei China, 2012 425 28.9 11 65 28.9
[35] Peter Paschka Columbus, OH, 2006 110 34 61 49 20 14%
[38] Ya-Zhen Qina Beijing, China, 2014 351 36.5 62 188 10 26.5%
[27] Satoshi Wakita Tokyo, Japan, 2011 26 46.1 0 26 NR 46.1%
[36] Hee-Jin Kim Seoul, South Korea, 2009 121 26.4 0 121 26.4 NR
[37] Baowei Jiao Shanghai, China, 2009 118 31.3 NR 118 NR 31.3%
[28] Sang Hyuk Park Seoul, Republic of Korea, 2013 50 44 NR 50 NR 44%
[29] Jungwon Huh Seoul, Korea, 2012 96 23 35 63 23 NR
[8] Sang Hyuk Park Seoul, Republic of Korea, 2011 116 38 38 78 18 20%
[3] Ludovica Riera Turin, Italy, 2013 49 14.2 14 9 6 7.2%
[4] Roberto Cairoli Naples, Italy, 2006 67 46.2 25 42 20 26%
[14] Nicolas Boissel Paris, France, 2006 103 17 47 56 22 12%
[30] Mayur Parihar Tamil Nadu, India, 2012 88 6.5 NR NR 6.5%
[31] JANA MARKOVA Czech Republic, 2009 36 33.3 34 26 13 20.3%
[32] O´scar Fuster, Valencia, Spain, 2009 55 15 24 30 10 5%
[33] Sang Hyuk Park Busan, Korea, 2015 92 9.8 21 71 5 4.8%
Note. NR = data not reported; Ref. = reference.
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Table 2 Indication of Methods Used and Follow-up Periods.
Ref. Author Methods Follow-up Median age
c-kit mutation
inv(16) t(8;21)
or overall
[9] Peter Paschka RT-PCR, sequencing, DHPLC 6.04 y 41 (18–74) NR
[24] Lars Bullinger RT-PCR, sequencing, DHPLC NR 42 (19–72) 50 (19–73)
[25] Yuan Wang qRT-PCR, direct-sequencing 3 mo NR 36 (18–54)
[26] Roberto Cairoli ARMS-PCR, sequencing NR 42 (15–60) NR
[16] Christopher Allen PCR/sequencing, DHPLC 10 y 39 (15–64) 39 (15–64)
[40] Jung-Hoon Yoon qRT-PCR 61.8 mo 39 (18–89)
[39] Di Wang PCR, sequencing 21 mo 28 (16–64) 32 (13–70)
[35] Peter Paschka Sequencing, DHPLC./RT-PCR 5.3 y 49 38
[38] Ya-Zhen Qina RQ-PCR, bidirectional sequencing 10 mo 38 (15–73)
[27] Satoshi Wakita MB-PCR/direct sequencing 3–112 mo NR 50.3 (3–72)
[36] Hee-Jin Kim Direct sequencing 27 mo 38 (18–69) 44 (15–71)
[37] Baowei Jiao QRT–PCR, direct sequencing 2 y NR 24 (3–72)
[28] Sang Hyuk Park RQ-PCR, direct sequencing. 24 mo NR 33.5 (2.0–69.0)
[29] Jungwon Huh Direct sequencing 33.5 mo 41 (15–75)
[8] Sang Hyuk Park RT-PCR, sequencing NR 44.0 (18.0–69.0)
[3] Ludovica Riera Q-PCR, direct sequencing 88 mo 51
[4] Roberto Cairoli PCR, sequencing 34 mo 51 (17–88) 40.5 (16–76)
[14] Nicolas Boissel RT-PCR, sequencing 4.4 y 33 (1–75)
[30] Mayur Parihar PCR, sequencing 25 mo 33 (16–61)
[31] Jana Markova Q-PCR, direct sequencing 27.1 mo 40.5(20.4–72.2)
[32] Oscar Fuster HRM, sequencing 17 mo NR
[33] Sang Hyuk Park PCR, sequencing 10 mo 47.0 (16.0–82.0) 41.0 (5.0–78.0)
Note. ARMS-PCR = amplification-refractory mutation system polymerase chain reaction; DHPLC = denaturing high performance liquid
chromatography; HRM = high resolution melting; NR = data not reported; PCR = polymerase chain reaction; Q-PCR = quantitative poly-
merase chain reaction; RT-PCR = reverse transcription polymerase chain reaction; RQ-PCR = real-time quantitative polymerase chain
reaction.
Prognostic Importance of C-KIT Mutations 5that this increase was more significant among patients with
t(8;21) [3,31,39]. Furthermore, the majority of the
reviewed studies evaluated other parameters such as OS,
relapse-free survival (RFS), and follow-up outcome in terms
of c-kit genotype marker presence or absence.
The effects of c-kit mutations on the OS of patients
With respect to c-kit mutations, CR rate was investigated in
16 studies on a CBF-AML population presenting with c-kit
mutations and was estimated to be between 40% and 100%
[3,8,14,25–31,33,34,36,37,39]. Effects of c-kit mutations
on RFS were investigated in 17 studies (p = .009–.34), and
it was reported as a significant variable among patients in
three articles [35,39,40]. Moreover, three studies that com-
pared the significance of RFS between CBF-AML patients
with inv(16) and t(8;21) and AML patients with t(8;21),
indicated its decline in the AML group; therefore, it can
be concluded that RFS rate is significant in the t(8;21) group
[8,11,38].
According to the results of 12 articles, RFS rate was esti-
mated to be 2.98–88.8%, while nine studies reported a RFS
rate reduction in the presence of c-kit mutations and wild-
type c-kit [4,16,26,28,30,32,34,35,37,40].Please cite this article in press as: Ayatollahi H et al., Prognostic Importa
kemia: A Systematic Review ..., Hematol Oncol Stem Cell Ther (2016), httHowever, two studies that evaluated the RFS rate in two
groups of AML patients with inv(16) and t(8;21), expressed a
RFS rate increment in the t(8;21) group compared with the
inv(16) group significantly [8,33].
OS was found in 21 articles, with a p value ranging
between .0004 and .9. In 18 papers, OS was measured in
all CBF-AML patients; according to their findings, OS had a
significant prognostic value (p > .001) [17,24–
26,28,29,31,34], while OS was not significant in c-kit muta-
tion prognosis determination in just one paper (p < .001)
[3,33,39].
In addition, five studies evaluated OS in two subgroups of
CBF-AML patients, including patients with inv(16) and t
(8;21), and the rate was measured in each group
[8,14,35,38,40]. OS rate was more significant in t(8;21)
patients compared with the cases with inv(16) in three of
these articles [8,38,40].
Among the reviewed articles, only two cases reported an
OS rate as a more significant marker in patients with inv(16)
[26,34] compared with t(8;21). Four other studies compared
OS rate between the above-mentioned groups, and their
findings were indicative of no significant differences
between patients with t(8;21) and inv(16) [3,4,31,39]. In
three studies, OS was measured in patients with t(8;21)nce of C-KIT Mutations in Core Binding Factor Acute Myeloid Leu-
p://dx.doi.org/10.1016/j.hemonc.2016.08.005
6 H. Ayatollahi et al.only, and this variable was not reported to be significant
among these patients [25,28,37].
In three articles, OS rate was not measured [27,30,32],
while the increase was reported by 12 researches among
c-kit mutant cases in a CBF-AML population [3,4,14,16,24,
26,29,30,34,36,37,40]. In these studies, the follow-up per-
iod ranged from 3 months to 10 years.
Discussion
Genetic alterations, such as c-kit mutations, are considered
as significant risk factors that provide essential prognostic
information about CBF-AML [34]. According to a Cox model,
some of the possible prognostic parameters of CBF-AML are
age, sex, WBC count, c-kit mutations, and cytogenetic
abnormalities of chromosome 22 [26].
CBF-AMLs are commonly associated with favorable prog-
nosis; however, this prognosis can be changed. Correspond-
ingly, only 50% of CBF-AML patients are able to preserve
long-term remission without any relapse [29]. Also, allo-
geneic stem cell transplantation has not been administered
in CBF-AML patients in CR [21,23].
Furthermore, based on the obtained results of this
review, c-kit mutations organize the main genetic aberra-
tions in the leukemogenesis of CBF-AML and are highly
prevalent among these patients. Therefore, c-kit mutations
are significant prognostic predictors in CBF-AML patients
with t(8;21) and inv(16), which are associated with poor
prognosis; however, current findings are inconsistent in this
regard [29,33]. In the reviewed articles for the present anal-
ysis, about 3,284 patients were evaluated in terms of c-kit
status. According to our findings, c-kit mutations have
direct effects on relapse and result in poor RFS, especially
with the D835 mutation; however, these mutations have
no significant effects on OS rate. However, c-kit mutations
can lead to WBC increments, especially in patients with
inv(16). In the reviewed studies, no significant association
was found between c-kit mutations and success rates of
CR and OS among CBF-AML patients.Conclusion
According to the results of current review, c-kit mutations
have poor prognostic significance in AML patients with t
(8;21); however, no definite results can be obtained accord-
ing to the prognostic effects of these mutations in AML
patients with inv(16). In the majority of the investigated
articles, c-kit mutations were observed to have better prog-
nostic effects on patients with inv(16) compared with those
with t(8;21). Therefore, it can be concluded that c-kit
mutations may cause relapse and WBC increments in CBF-
AML adults without any significant prognosis in their
survival.
One of the major limitations of present study was lack of
prospective controlled studies in the review of the selected
articles. Furthermore, due to limited data accessibility,
findings of the current study can be used for AML prognosis
evaluation and patients’ guidance. It seems that it is neces-
sary to recognize more efficient prognostic indicators and
therapeutic strategies to determine AML risks.Please cite this article in press as: Ayatollahi H et al., Prognostic Importa
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